InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
79.75
(
0.00%
)
Bitcoin
67,996.06
(
0.29%
)
Post# of 4764
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: None

Saturday, 03/01/2008 12:09:15 PM

Saturday, March 01, 2008 12:09:15 PM

Post# of 4764
New papers rearding anti-EGFR therapy: dosing of Erbitux every two weeks, resistance to anti-EGFR therapy by ErbB-3 activation, and correlation of miRNA levels with response to small molecule EGFR inhibitors.

http://www.ncbi.nlm.nih.gov/pubmed/18305055?dopt=AbstractPlus

http://www.ncbi.nlm.nih.gov/pubmed/18297114?dopt=AbstractPlus

http://www.ncbi.nlm.nih.gov/pubmed/18304967?ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Regards,

biophud
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up